New River Pharmaceuticals — First Albany Capital Annual Growth Conference 2005
21 slides from New River Pharmaceuticals's conference presentation, Dec 7, 2005

Slide 1: First Albany Capital Annual Growth Conference
Exhibit 99.1 First Albany Capital Annual Growth Conference December 7, 2005 RJ Kirk (Chairman and CEO) Krish Krishnan (CFO/COO)

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views as to the Company’s clinical trials, regulatory approval process, product development, research programs and other future events and operations. These forward-looking statement

Slide 3: Investment Thesis
Investment Thesis A platform technology yielding proprietary products that offer significant clinical advantages with low technical risk and shorter development pathway, facing timely market demand, in a favorable regulatory climate.

Slide 4: Pipeline Update
Pipeline Update n NRP104 • New Drug Application (NDA) on NRP104 filed on December 6, 2005 • 2 of 3 clinical abuse liability studies completed and meet objectives • Remaining study is on-going and will be submitted during the review cycle n NRP290 • Phase I clinical study completed • Phase I/II dose

Slide 5: Meaning of 'Abuse Resistance'
Meaning of ‘Abuse Resistance’ n Policy makers encourage and support technologies that meaningfully inhibit abuse of therapeutics that otherwise are subject to abuse and diversion n Track record of formulation and packaging approaches has been poor n No existing ‘standard’ test battery to measure abu

Slide 6: Regulatory Scheduling of Stimulants in U.S.
Regulatory Scheduling of Stimulants in U.S. n Five classes of schedules under Controlled Substance Act of 1970 n Substances with high potential for abuse that have no currently accepted medical use in treatment in the United States are placed in Schedule I n Substances with currently accepted medica

Slide 7: NRP104: Scheduling
NRP104: Scheduling n Currently unscheduled by the DEA in development n NRP104 is pharmacologically inactive unless biotransformed via enzymatic reactions n Results to date indicate that NRP104 would be unattractive to abuse • Tampering with NRP104 capsules to extract amphetamine is cumbersome, compl

Slide 8: NRP104 Extraction Studies
NRP104 Extraction Studies

Slide 9: NRP104: Relevant abuse liability studies
NRP104: Relevant abuse liability studies n Preclinical • Discrimination studies in monkeys • Parenteral routes of administration studies • LD50 studies • Binding and metabolic studies n Clinical • Dose ranging and dose attenuation study (NRP104.A01) • Intravenous study (NRP104.A02) • Comparator stud

Slide 10: Overview of Extraction Studies on NRP104
Overview of Extraction Studies on NRP104 n Kitchen tests n Garage tests n Extraction studies • Enzymatic solutions • Base solutions • Buffered solutions • Acidic solutions

Slide 11: NRP104: Kitchen Tests
NRP104: Kitchen Tests % release of amphetamine from conjugate Conc. HCL Vinegar Tap Water Saturated Saturated Conc. NaOH Baking Powder Baking Soda NRP104 0% 0% 0% 0% 0% 0% Range of pH from acidic to basic Samples were heated at boiling for 60 minutes * % AUC

Slide 12: NRP104: Garage Tests
NRP104: Garage Tests d-amphetamine (1) (wt. % d-amphetamine) Solution (active ingredients) 1h 24 h Lysol® Toilet (HCl) 0 0 Crete-nu (75% H3PO4) 0 0 CLR® (sulfamic acid, hydroxyacetic acid) 0 0 Roebic® Drain Flow™ (90% H2SO4) 0 0 Crown® Muriatic Acid (31.45% HCl) 0 0 Liquid-Plumr® (NaOH, NaClO, H2O2)

Slide 13: NRP104: Extraction studies in enzymatic solutions
NRP104: Extraction studies in enzymatic solutions d-amphetamine (1) (wt. % d-amphetamine) 1h 24 h Solution Cellfood® 0 0 Drano® Max with Bacteria 0 0 VitälZym™ 0 0 Omnigest™ 0 0 Enforcer® Septic 0 0 Rid-X® Septic 0 0 Esterase 0 19 Pancreatin 0 0 Pepsin 0 0 Pronase 0 24 The enzyme list presented abov

Slide 14: NRP104: Extraction Studies in Base Solutions
NRP104: Extraction Studies in Base Solutions n Scope • Concentrations: 3M, 6M, 9M and 12M • Temperature conditions: Ambient, 90o C and 150o C (reflux) • Measurement time points (min.): 5, 15, 30, 60, 120, 180, 240 • Sodium hydroxide, Potassium hydroxide, Sodium carbonate, Ammonium hydroxide, Diethyl

Slide 15: NRP104: Extraction studies in Buffered Solutions
NRP104: Extraction studies in Buffered Solutions n Scope • Temperature conditions: Ambient, 90o C and 150o C (reflux) • Measurement time points (min.): 5, 15, 30, 60, 120, 180, 240 • Buffers: Glycine/hydrochloric acid, Sodium acetate/acetic acid, Citric acid/sodium citrate, Potassium dihydrogen orth

Slide 16: NRP104: Extraction Studies in Acidic Solutions
NRP104: Extraction studies in Acidic Solutions n Scope • Acids: Hydrochloric, Acetic, Sulfuric, Phosphoric, Nitric and Citric • Measurement time points (min.): 5, 15, 30, 60, 120, 180, 240 • Concentrations: 10%, 25%, 50%, 75% and concentrated • Temperature conditions: Ambient, 90o C and 150o C (refl

Slide 17: NRP104: Extraction Studies in Acidic Solutions (cont'd)
NRP104: Extraction Studies in Acidic Solutions (cont’d) n Scope • Solvents: 1-Butanol, Chloroform, Diethyl ether, Ethyl acetate, n-Heptane Methylene chloride • Types: Neutralized extraction and non-neutralized extraction n Results • Non-Neutralized extraction Ø Recoveries of amphetamine from a highl

Slide 18: NRP104: Extraction complexity
NRP104: Extraction complexity NRP104 Other Marketed Products 1. 1. NRP104 Currently Marketed capsules Products 2. 2. Extract NRP104 Extract Drug Substance d-Amphetamine 3. 3. Hydrolyze Drug d-Amphetamine Substance 4. Additional reduction in recovery percentages of Extract Amphetamine amphetamine (ap

Slide 19: Conclusion
Conclusion n Drug substance in NRP104 capsules is pharmacologically inactive • Drug substance has to be metabolized or biotransformed via enzymatic reactions to release d-amphetamine • Drug substance in currently marketed stimulants is active n Extracting amphetamine from NRP104 capsules is a comple

Slide 20: New River Pharmaceuticals
NE W RIVER PHARMACEUTICALS

Slide 21
Source: SEC EDGAR · 8-K filed Dec 7, 2005
More decks from New River Pharmaceuticals Inc
Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 20078 slides · Feb 6, 2007
Bear Stearns 19th Annual Investor Conference 200614 slides · Sep 12, 2006
Technical Presentation (June 2006)46 slides · Jun 26, 2006
Technical Presentation (June 2006)8 slides · Jun 20, 2006
Technical Presentation (June 2006)19 slides · Jun 19, 2006
Merrill Lynch Healthcare Conference 200610 slides · Feb 7, 2006